US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
オーストラリア
ASX
Anagenics Ltd (AN1) 銘柄情報

Anagenics Ltd (AN1)

0.007

0.00

(0.00%)

終了 7月4日 3:00PM

Anagenics Ltd (AN1) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.007

( - )

買値

0.007

売値

0.008

出来高

0.00

0.00 日の範囲 0.00

0.004 52 週間の範囲 0.009

時価総額

前日終値

0.007

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 638,538

発行済株式数

985,450,795

配当利回り

PER

-4.87

1 株当たり利益 (EPS)

-0

歳入

4.83M

純利益

-645.06k

Anagenics Limited engages in the health wellness and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name. It also imports and distributes skin care and wellbeing ... Anagenics Limited engages in the health wellness and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name. It also imports and distributes skin care and wellbeing products to spas, clinics, salons, retail stores, and online in Australia, New Zealand, and the Pacific Islands. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia. 詳細を表示

セクター

Consumer Staples

業界

Consumer Products - Household & Personal

ウェブサイト

anagenics.com

本社

Sydney, Australia

設立

2026

Anagenics Ltd is listed in the Consumer Staples sector of the オーストラリア証券取引所 with ticker AN1. The last closing price for Anagenics was AUD0.01. Over the last year, Anagenics shares have traded in a share price range of AUD 0.004 to AUD 0.009.

Anagenics currently has 985,450,795 shares in issue. The market capitalisation of Anagenics is AUD6.90 million. Anagenics has a price to earnings ratio (PE ratio) of -4.87.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0.007	0.008	0.007	188781	0.007	DE
4	0.001	16.6666666667	0.006	0.008	0.006	478925	0.0068848	DE
12	0.001	16.6666666667	0.006	0.009	0.0055	651643	0.00710962	DE
26	0.001	16.6666666667	0.006	0.009	0.005	854733	0.00677166	DE
52	0.002	40	0.005	0.009	0.004	819611	0.00586546	DE
156	-0.008	-53.3333333333	0.015	0.028	0.004	643866	0.00757922	DE
260	-0.05	-87.7192982456	0.057	0.061	0.004	425275	0.01101107	DE

AN1 - Frequently Asked Questions (FAQ)

What is the current Anagenics Ltd share price?

The current share price of Anagenics Ltd is AUD 0.007

How many Anagenics Ltd shares are in issue?

Anagenics Ltd has 985,450,795 shares in issue

What is the market cap of Anagenics Ltd?

The market capitalisation of Anagenics Ltd is AUD 6.9M

What is the 1 year trading range for Anagenics Ltd share price?

Anagenics Ltd has traded in the range of AUD 0.004 to AUD 0.009 during the past year

What is the PE ratio of Anagenics Ltd?

The price to earnings ratio of Anagenics Ltd is -4.87

What is the cash to sales ratio of Anagenics Ltd?

The cash to sales ratio of Anagenics Ltd is 1.43

What is the registered address of Anagenics Ltd?

The registered address for Anagenics Ltd is 68 Pitt Street, Sydney, New South Wales, 2000

What is the Anagenics Ltd website address?

The website address for Anagenics Ltd is anagenics.com

Which industry sector does Anagenics Ltd operate in?

Anagenics Ltd operates in the Consumer Products - Household & Personal sector

j e d

This is the biggest thing since the Advent acquisition, if not bigger.

JAB65

Never thought about that. That would certainly save them a few hundred million. Is there enough capacity, compression or whatever the criteria is to piggyback on Williams? Would they prefer to have their own control with a new station?

fredscott36

fredscott36 2分前

..dude......will get 'em both, and the G-wagon is ordered, and the 4-runner......not firm on the wrangler, but definitely a wrangler............gotta fill up the garages with a new fleet.........boys toys................($40mios in the tip jar??)...............

.....the POS.....???.

US Market News

US Market News 3分前

Robert Half receives three Canadian HR Reporter Readers' Choice Awards 2026, for 11th consecutive yearJuly 3, 2026 12:38 PM
PR Newswire (Canada) class="legendSpanClass"TORONTO, class="legendSpanClass"July 3, 2026 /CNW/ - Global talent so

KeepItRealistic

KeepItRealistic 4分前

$OSRH to new long investors buy 10k shares and HOLD and while turning your 10k shares to 60k shares 👇

• Details: One non-transferable CVR per share held as of the record date (targeted for July 31, 2026). Subject to legal counsel approval.

• Tiered Rewards: T

williamssc

williamssc 6分前

Slide16 “Overall Conclusions: The survival benefit associated with DCVax-L treatment reflects a true treatment affect and was underestimated in the original analysis”

https://nwbio.com/wp-content/uploads/NWBT-BNOS-slides-7-3-26MB-LP-final.pdf

NASDAQ2020

NASDAQ2020 8分前

i will wait for Monday to grab some more ??

GoodGuyBill

GoodGuyBill 8分前

Brazen22, you’re trying to reduce three years of regulatory progress to one sentence: “You don’t have an approved MAA.”

Of course we don’t — yet. Approval is the destination. We have a validated MAA. What matters is whether NWBO has completed the steps that regulators require before a

NASDAQ2020

NASDAQ2020 8分前

THATS WHEN i ACCUMULATE. At The hammerbottom.

nowwhat2

nowwhat2 8分前

Nonbelievers . . . . . C L E A R The R U N W A Y
$3.50 CDN is pretty strong support.

https://investorshub.advfn.com/uimage/uploads/2026/7/3/vwgethg_july_3_2y_plunge_sell.jpg

rizona

rizona 10分前

Slides! JAMA study UNDERESTIMATED survival benefit

https://nwbio.com/wp-content/uploads/NWBT-BNOS-slides-7-3-26MB-LP-final.pdf

rosemountbomber

rosemountbomber 11分前

I agree with your thinking and also what needs to be considered is after decimating the board, just a desire to be acquired doesn’t automatically make that happen. Some other party has to be interested in acquiring Amarin. What happens then if no one steps up?

chereb19

chereb19 12分前

This is another post built on false equivalence. Sharing Y-90 doesn't make two products the same any more than sharing aspirin makes every painkiller identical.

You keep calling them competitors while ignoring they're fundamentally different technologies. One is a hydrogel platform, t

NASDAQ2020

NASDAQ2020 13分前

Im glad I held my shares past $0.15

Idunno

Idunno 13分前

And don’t forget your buddy, AF. … .. .

Doc logic

Doc logic 13分前

HappyLibrarian,

You are mistakenly overstating my claim which is a common problem so no harm no foul. Manufacturing transition preparedness is what I am suggesting must be in place. Artisan will be utilized to start as NWBO has consistently stated and the MIA is based on that model.

rcaselli

rcaselli 14分前

Just knowing JCTB1 is here is good enuf for me, okay.
See ya all topside….
$LBRG

Idunno

Idunno 14分前

Have at it Brazen! ;) … .. . :)

CatfishHunter

CatfishHunter 16分前

Every biotech founder believes their design choice was the right one — that’s true of BetaGlue’s surgeon-founder and it was true of Fisher/Korenko too. Design rationale explains intent, not outcome. The question that matters is what the trial data shows for each product, not why either team picked t

asp42001

asp42001 17分前

Digital USIO & AI Payment Potential:

(USIO In-Part):

"Embedded payments are the hidden engine under the hood of the apps and platforms we use every day. When you buy a ticket through a sports app or pay for a round of golf lessons online, embedded payments are doing the

BigBadWolf

BigBadWolf 17分前

$Ownership😘 of @ this point w/ irrefutable DD
🤔https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177573771&txt2find=reactor

mgland

mgland 18分前

https://x.com/thommic/status/2072760144774005081

GTF

Just so you know the clock on the 12 month restricted period for SNTX divvy shares began on June 17th, 2026. It doesn't matter that the deliverance of shares to the gtvh shareholders is taking some time. The clock begins when SNTX creates and issues the shares...meaning the day OTCmarkets shows the

manibiotech

manibiotech 20分前

I like this line in couple of PSM analysis slides:

“ Conclusion: Based on these more precisely matched comparisons,
the survival benefit with DCVax-L was likely underestimated
in the original analysis”

Very encouraging . Now let’s see when MHRA does its jo

Xpedra Resources (PK)

Vanguard FTSE CDN Capped... (EM)

Reitmans Cda (PK)

Community Bancorp of San... (QX)

Janus Henderson

Peak Processing

Invictus Energy

Provaris Energy

Classic Minerals

Lifeist Wellness

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。